Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#121 / 200 Total
HOTH - Hoth Therapeutics Inc - Stock Price Chart
TickerHOTH [NASD]
CompanyHoth Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap17.18MEPS (ttm)-1.15
P/E-EPS this Y65.87%
Forward P/E-EPS next Y0.48%
PEG-EPS past 5Y27.96%
P/S-EPS next 5Y26.83%
P/B1.48EPS Q/Q41.13%
Dividend-Sales Q/Q-
Insider Own0.49%Inst Own2.30%
Insider Trans0.00%Inst Trans24.87%
Short Float8.77%EarningsMay 28
Analyst Recom1.00Target Price5.00
Avg Volume1.13M52W Range0.58 - 3.80
Jun-27-25 11:50AM Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-25-25 10:40AM Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study (TipRanks) -7.03%
08:38AM Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market (GlobeNewswire)
08:27AM Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. (PR Newswire)
Jun-24-25 10:36AM Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects (PR Newswire)
Jun-23-25 08:03AM Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy (PR Newswire)
Jun-18-25 01:34PM Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth (PR Newswire)
08:22AM Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway (PR Newswire)
Jun-16-25 08:00AM Hoth Therapeutics to Attend 2025 BIO International Convention (PR Newswire)
Jun-12-25 09:17AM Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases (PR Newswire) +7.58%
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knie RobbCEO and PresidentAug 16 '24Buy0.6725,00016,75058,131Aug 19 08:00 AM
VHC - Virnetx Holding Corp - Stock Price Chart
TickerVHC [NYSE]
CompanyVirnetx Holding Corp
CountryUSA
IndustrySoftware - Infrastructure
Market Cap57.60MEPS (ttm)-4.61
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y2.01%
P/S-EPS next 5Y-
P/B1.58EPS Q/Q14.53%
Dividend-Sales Q/Q-100.00%
Insider Own18.07%Inst Own10.62%
Insider Trans0.00%Inst Trans-7.98%
Short Float4.28%EarningsMay 15/b
Analyst Recom1.00Target Price36.00
Avg Volume13.34K52W Range3.68 - 13.89
May-14-25 06:55PM VirnetX: Q1 Earnings Snapshot (Associated Press Finance) -6.38%
Dec-09-24 06:25AM VirnetX Announces New Chief Technical Officer (PR Newswire)
Nov-21-24 03:17PM VirnetX To Webcast Company Update With CEO Kendall Larsen (PR Newswire)
Nov-13-24 04:48PM VirnetX: Q3 Earnings Snapshot (Associated Press Finance)
Oct-09-24 09:25AM VirnetX Establishes CRADA with AFRL/RI (PR Newswire)
Sep-04-24 04:15PM VirnetX Receives NYSE Notification (PR Newswire)
Aug-16-24 09:52PM VHC Stock Earnings: VirnetX Holding Reported Results for Q2 2024 (InvestorPlace)
Aug-15-24 05:15AM VirnetX: Q2 Earnings Snapshot (Associated Press Finance)
Jul-22-24 09:25AM VirnetX Participates at RIMPAC 2024 (PR Newswire)
May-16-24 08:53AM VHC Stock Earnings: VirnetX Holding Reported Results for Q1 2024 (InvestorPlace)
VirnetX Holding Corp. engages in the provision of Internet security software and technology solutions to facilitate secure network communications, including 5G and 4G LTE. Its products include War Room, Gabriel secure gateway, collaboration suite, secure domains, secure communication platform, and connection technology. The company was founded on August 5, 2005 and is headquartered in Zephyr Cove, NV.
SLDP - Solid Power Inc - Stock Price Chart
TickerSLDP [NASD, RUT]
CompanySolid Power Inc
CountryUSA
IndustryAuto Parts
Market Cap450.20MEPS (ttm)-0.50
P/E-EPS this Y9.26%
Forward P/E-EPS next Y-2.04%
PEG-EPS past 5Y-27.17%
P/S22.29EPS next 5Y17.79%
P/B1.15EPS Q/Q28.82%
Dividend-Sales Q/Q1.06%
Insider Own25.18%Inst Own26.02%
Insider Trans-1.07%Inst Trans7.31%
Short Float12.44%EarningsMay 06/a
Analyst Recom1.00Target Price2.00
Avg Volume4.40M52W Range0.68 - 2.70
Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liebscher JamesFormer OfficerJun 11 '25Proposed Sale1.8993,961177,588Jun 11 01:57 PM
Liebscher JamesFormer OfficerJun 11 '25Proposed Sale1.91271,796519,159Jun 11 12:06 PM
Roe Lesa BDirectorMay 29 '25Sale1.6929,00049,010239,049May 30 04:31 PM
Roe Lesa BDirectorMay 29 '25Proposed Sale1.6929,00049,016May 29 11:24 AM
Goldberg Steven HDirectorMay 27 '25Sale1.6282,365133,481118,808May 28 04:23 PM
RSLS - ReShape Lifesciences Inc - Stock Price Chart
TickerRSLS [NASD]
CompanyReShape Lifesciences Inc
CountryUSA
IndustryMedical Devices
Market Cap6.25MEPS (ttm)-210.70
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y80.05%
P/S0.87EPS next 5Y-
P/B0.28EPS Q/Q114.00%
Dividend-Sales Q/Q-42.75%
Insider Own8.37%Inst Own10.04%
Insider Trans0.00%Inst Trans0.28%
Short Float43.24%EarningsMay 21/b
Analyst Recom1.00Target Price1450.00
Avg Volume2.85M52W Range2.23 - 414.99
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, the Obalon Balloon System, and the Diabetes Bloc-Stim Neuromodulation device. The firm sells the Lap-Band worldwide and is managed in the following geographical regions: United States, Australia, Europe, and the Rest of World. The company was founded in December 2002 and is headquartered in Irvine, CA.
BMEA - Biomea Fusion Inc - Stock Price Chart
TickerBMEA [NASD]
CompanyBiomea Fusion Inc
CountryUSA
IndustryBiotechnology
Market Cap106.06MEPS (ttm)-3.55
P/E-EPS this Y52.73%
Forward P/E-EPS next Y13.33%
PEG-EPS past 5Y-149.32%
P/S-EPS next 5Y24.39%
P/B2.43EPS Q/Q26.59%
Dividend-Sales Q/Q-
Insider Own12.70%Inst Own40.44%
Insider Trans0.00%Inst Trans16.93%
Short Float24.03%EarningsMay 05/a
Analyst Recom1.57Target Price11.67
Avg Volume2.40M52W Range1.29 - 13.07
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hitchcock Michael J.M.DirectorSep 30 '24Buy10.0610,000100,60015,000Oct 01 04:30 PM
CV - CapsoVision Inc - Stock Price Chart
TickerCV [NASD]
CompanyCapsoVision Inc
CountryUSA
IndustryMedical Devices
Market Cap213.65MEPS (ttm)-0.16
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S17.74EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q11.50%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume3.65M52W Range3.49 - 5.72
Jul-03-25 11:50AM CapsoVision Announces Closing of Initial Public Offering (GlobeNewswire) +25.71%
Jul-01-25 09:08PM CapsoVision Announces Pricing of Initial Public Offering (GlobeNewswire)
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. It offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). The company also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premise video access and download solution; CapsoAccess, a Capsule data access system; CapsoView, a data access reading device for viewing capsule videos; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. It serves gastrointestinal medical practices, clinics, and hospitals. The company sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May, 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
PMVP - PMV Pharmaceuticals Inc - Stock Price Chart
TickerPMVP [NASD]
CompanyPMV Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap68.57MEPS (ttm)-1.17
P/E-EPS this Y-35.38%
Forward P/E-EPS next Y-14.04%
PEG-EPS past 5Y-14.06%
P/S-EPS next 5Y-15.79%
P/B0.43EPS Q/Q-13.07%
Dividend-Sales Q/Q-
Insider Own15.79%Inst Own67.95%
Insider Trans-1.71%Inst Trans-7.54%
Short Float1.99%EarningsMay 09/b
Analyst Recom1.00Target Price10.00
Avg Volume246.20K52W Range0.81 - 1.82
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ticktin RobertGeneral Counsel & COOJul 01 '25Sale1.0623,15124,65198,695Jul 03 07:51 PM
Jalota DeepikaChief Development OfficerJul 01 '25Sale1.0633,06535,19889,959Jul 03 07:50 PM
Carulli MichaelChief Financial OfficerJul 01 '25Sale1.0628,24930,07760,146Jul 03 07:49 PM
Mack David HenryPresident and CEOJul 01 '25Sale1.0658,41162,179536,133Jul 03 07:48 PM
Mack David HenryPresident and CEODec 03 '24Option Exercise0.5391,75048,628534,210Jan 22 04:37 PM
ELDN - Eledon Pharmaceuticals Inc - Stock Price Chart
TickerELDN [NASD, RUT]
CompanyEledon Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap204.79MEPS (ttm)-2.21
P/E-EPS this Y-18.67%
Forward P/E-EPS next Y-12.36%
PEG-EPS past 5Y50.24%
P/S-EPS next 5Y-14.98%
P/B1.79EPS Q/Q89.31%
Dividend-Sales Q/Q-
Insider Own7.58%Inst Own59.42%
Insider Trans0.00%Inst Trans-0.02%
Short Float2.40%EarningsMay 14/a
Analyst Recom1.00Target Price9.00
Avg Volume340.18K52W Range2.30 - 5.54
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
KPTI - Karyopharm Therapeutics Inc - Stock Price Chart
TickerKPTI [NASD]
CompanyKaryopharm Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap40.18MEPS (ttm)-13.26
P/E-EPS this Y21.36%
Forward P/E-EPS next Y65.43%
PEG-EPS past 5Y27.91%
P/S0.28EPS next 5Y47.98%
P/B-EPS Q/Q42.94%
Dividend-Sales Q/Q-9.39%
Insider Own7.84%Inst Own50.13%
Insider Trans-5.04%Inst Trans-10.23%
Short Float25.41%EarningsMay 12/a
Analyst Recom2.00Target Price23.25
Avg Volume77.20K52W Range3.51 - 16.95
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paulson Richard A.President and CEOMay 06 '25Sale7.122361,68082,503May 07 05:03 PM
Rangwala ReshmaEVP & Chief Medical OfficerApr 23 '25Sale6.174192,58528,853Apr 24 04:40 PM
Paulson Richard A.President and CEOApr 04 '25Sale3.7424591682,739Apr 07 04:59 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerMar 04 '25Sale6.293,44521,66934,314Mar 06 04:27 PM
Paulson Richard A.President and CEOMar 04 '25Sale6.2911,69473,55582,984Mar 06 04:27 PM
LIQT - LiqTech International Inc - Stock Price Chart
TickerLIQT [NASD]
CompanyLiqTech International Inc
CountryDenmark
IndustryPollution & Treatment Controls
Market Cap17.11MEPS (ttm)-1.48
P/E-EPS this Y50.61%
Forward P/E-EPS next Y39.51%
PEG-EPS past 5Y-
P/S1.14EPS next 5Y-
P/B1.14EPS Q/Q40.47%
Dividend-Sales Q/Q9.02%
Insider Own27.71%Inst Own39.27%
Insider Trans0.00%Inst Trans-2.17%
Short Float1.42%EarningsMay 14/b
Analyst Recom1.00Target Price3.60
Avg Volume18.32K52W Range1.34 - 3.20
LiqTech International, Inc. is a clean technology company, which engages in the provision of gas and liquid purification products by manufacturing ceramic silicon carbide filters. It operates through the following segments: Water, Ceramics, Plastics, and Corporate. The firm specializes in ceramic membranes for liquid filtration systems and diesel particulate filters (DPFs) to control soot exhaust particles from diesel engines. The company was founded by Lasse Andreassen on July 1, 2004 and is headquartered in Ballerup, Denmark.
18910111213141516171820